B-RAF inhibitors showed adjuvant efficacy in combined treatment with standard chemotherapy in patients with melanoma; disappointingly, however, after less than six months, disease relapse was resistant to inhibitors, and consequently to therapy. Here, BRAF is linked to melanoma.